Shareholders to Vote on Massive Dilution, Reverse Split, and Equity Plan Expansion Amidst Going Concern Warning

summarizeSummary

bioAffinity Technologies is seeking shareholder approval for a reverse stock split, a massive increase in its equity incentive plan, and authorization for highly dilutive future offerings, all critical steps to address its going concern warning and secure necessary capital.

check_boxKey Events

• Annual Meeting Scheduled with Critical Proposals

  The company will hold its Annual Meeting of Stockholders on April 30, 2026, to vote on ten key proposals, many of which are highly dilutive and crucial for the company's financial stability.

• Authorization for Highly Dilutive Future Offerings

  Shareholders are asked to approve the authorization to issue up to 10 million shares or $10 million in one or more non-public offerings, representing over 200% potential dilution relative to current outstanding shares and exceeding the company's current market capitalization.

• Significant Equity Incentive Plan Expansion

  A proposal seeks to increase the shares reserved for the 2024 Equity Incentive Plan from 66,666 to 1,000,000 shares, a substantial increase that could result in over 20% dilution to existing shareholders.

• Reverse Stock Split Proposed to Maintain Nasdaq Listing

  The Board is seeking approval for a reverse stock split at a ratio between 1-for-2 and 1-for-250, primarily to increase the per-share price and regain compliance with Nasdaq's minimum bid price requirement. This follows a preliminary filing on March 5, 2026.

auto_awesomeAnalysis

This definitive proxy statement outlines critical proposals for bioAffinity Technologies' upcoming annual meeting, directly addressing the company's previously disclosed 'going concern' warning. The most significant proposals involve authorizing substantial future dilution, including a potential capital raise of up to $10 million (exceeding the current market cap) through non-public offerings, which could dilute existing shareholders by over 200%. Additionally, the company seeks to dramatically increase its equity incentive plan share pool by over 900,000 shares and approve anti-dilution adjustments for existing warrants and preferred stock, further increasing potential share issuance. While a reverse stock split is proposed to maintain Nasdaq listing, the cumulative effect of these capital-raising and equity compensation proposals indicates a desperate need for funds that will come at a very high cost to current shareholders. Investors should be aware of the severe dilutive impact these measures, if approved, will have on their ownership.